Drugs / meso-2,3-dimercaptosuccinic acid
meso-2,3-dimercaptosuccinic acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00376194 | Sep 2006 → Mar 2007 | autism | National Institute of Mental Health (NIMH) | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | meso-2,3-dimercaptosuccinic acid | “The present investigation is a double-blind, randomized placebo-controlled study of the oral chelating agent meso-2,3-dimercaptosuccinic acid (DMSA; succimer) among 120 children” NCT00376194 ↗ |
| Known as | DMSA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00376194 ↗ |
| Known as | succimer | “The present investigation is a double-blind, randomized placebo-controlled study of the oral chelating agent meso-2,3-dimercaptosuccinic acid (DMSA; succimer) among 120 children” NCT00376194 ↗ |
| Route | Oral | “DMSA, an oral chelating agent” NCT00376194 ↗ |